OncoMatch/Clinical Trials/NCT06326463
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
Is NCT06326463 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Fludarabine and Cyclophosphamide for hematologic malignancy.
Treatment: Fludarabine · Cyclophosphamide · CD70-CAR T cell infusion (Autologous) · Mesna — The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse). Primary Objective To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD70-CAR T cells in patients (≤21 years) with recurrent/refractory CD70+ hematological malignancies after lymphodepleting chemotherapy. Secondary Objectives To evaluate the antileukemic activity of CD70-CAR T cells. We will determine the anti- leukemic activity of the CD70-CAR T cells in the bone marrow and in the treatment of extramedullary disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD70 overexpression (CD70+)
Relapsed/refractory CD70+ hematological malignancy
Allowed: CD19 negative/dim
CD70 positive and CD19 negative/dim or patients otherwise ineligible for CD19-directed therapies
Prior therapy
Must have received: induction chemotherapy
Refractory disease: Patients with persistent disease despite 3 cycles of induction chemotherapy
Must have received: allogeneic hematopoietic stem cell transplant
Patients with relapse after allogeneic HSCT
Cannot have received: donor lymphocyte infusion
Exception: within 28 days prior to apheresis
have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- St. Jude Children's Research Hospital · Memphis, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify